Madrigal Pharmaceuticals, Inc.
MDGL
$301.66
-$6.12-1.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 44.45% | 29.62% | -3.00% | -31.51% | -13.63% |
| Total Depreciation and Amortization | 21.81% | 11.61% | 58.93% | 18.31% | 5.19% |
| Total Amortization of Deferred Charges | 0.42% | 1.69% | -27.94% | -13.01% | 11.72% |
| Total Other Non-Cash Items | 1.69% | -28.54% | 22.62% | 34.00% | 17.31% |
| Change in Net Operating Assets | -392.48% | 368.10% | 63.67% | -235.29% | 4,604.84% |
| Cash from Operations | -55.99% | 50.36% | 9.53% | -86.60% | 5.87% |
| Capital Expenditure | 74.97% | -494.66% | 63.31% | 65.54% | -205.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 76.31% | -65.30% | -223.94% | 127.25% | -814.49% |
| Cash from Investing | 76.31% | -65.76% | -224.52% | 127.08% | -821.37% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 164.96% | -94.44% | -76.62% | 19.54% | 10,209.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 164.96% | -94.44% | -76.62% | 19.54% | 2,351.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.35% | -113.08% | -123.52% | 1,280.35% | 350.05% |